
Novartis AG
NVSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 28, 2026 | Morgan Stanley | Thibault Boutherin | $163.00(+4%) | $156.86 | TheFly |
| Oct 6, 2026 | Morgan Stanley | Thibault Boutherin | $156.00(+11%) | $140.85 | TheFly |
| Sep 10, 2026 | HSBC | $136.00(-1%) | $137.48 | TheFly | |
| Mar 26, 2026 | Morgan Stanley | Thibault Boutherin | $170.00(+14%) | $149.70 | TheFly |
| Dec 10, 2025 | HSBC | $112.00(-15%) | $131.01 | TheFly | |
| Dec 3, 2025 | Morgan Stanley | $143.00(+8%) | $132.28 | TheFly | |
| Oct 29, 2025 | CFRA | Wan Nurhayati | $126.00(+2%) | $123.33 | StreetInsider |
| Oct 30, 2024 | BMO Capital | Etzer Darout | $120.00(+9%) | $109.91 | StreetInsider |
| Sep 5, 2024 | Goldman Sachs | James Quigley | $121.00(+1%) | $119.38 | TheFly |
| Jul 19, 2024 | BMO Capital | Etzer Darout | $118.00(+11%) | $106.13 | StreetInsider |
| Apr 23, 2024 | CFRA | Wan Nurhayati | $108.00(+11%) | $97.27 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Deutsche Bank | downgrade | Hold →Sell | Oct 30, 2026 |
| HSBC | upgrade | Reduce →Hold | Sep 10, 2026 |
| Morgan Stanley | maintain | Overweight | Mar 26, 2026 |
| Barclays | upgrade | Underweight →Equal Weight | Jan 6, 2026 |
| JP Morgan | upgrade | Neutral →Overweight | Dec 8, 2025 |
| Goldman Sachs | downgrade | Neutral →Sell | Sep 12, 2025 |
| UBS | downgrade | Buy →Neutral | Feb 13, 2025 |
| Erste Group | downgrade | Buy →Hold | Nov 19, 2024 |
| BMO Capital | maintain | Market Perform | Oct 30, 2024 |
| B of A Securities | downgrade | Buy →Neutral | Sep 11, 2024 |
| Goldman Sachs | downgrade | Buy →Neutral | Sep 5, 2024 |
| Jefferies | downgrade | Buy →Hold | Sep 3, 2024 |
| Jefferies | maintain | Buy | Jul 2, 2024 |
| BMO Capital | maintain | Market Perform | Apr 24, 2024 |
| Morgan Stanley | upgrade | Underweight →Equal Weight | Sep 25, 2023 |
| Wolfe Research | downgrade | Outperform →Peer Perform | May 9, 2022 |
| Exane BNP Paribas | downgrade | Outperform →Neutral | Dec 6, 2021 |
| Bryan Garnier | downgrade | Buy →Neutral | Dec 3, 2021 |
| Deutsche Bank | downgrade | Hold →Sell | Sep 20, 2021 |
| Argus Research | downgrade | Buy →Hold | Mar 10, 2021 |
| Cowen & Co. | downgrade | Outperform →Market Perform | Feb 1, 2021 |
| Morgan Stanley | upgrade | Equal Weight →Overweight | Sep 1, 2020 |
| Guggenheim Securities | downgrade | Buy →Neutral | Feb 25, 2020 |
| Guggenheim | downgrade | Buy →Neutral | Feb 25, 2020 |
| Guggenheim | upgrade | Neutral →Buy | Apr 25, 2019 |
Earnings History
Next report: Feb 3, 2027 · EPS est. $2.23| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 27, 2026 | $2.46 | $2.25 | $14.52B | $14.53B |
| Jul 21, 2026 | $2.41 | $2.17 | $14.41B | $14.07B |
| Apr 28, 2026 | $1.99 | $2.11 | $13.11B | $13.44B |
| Feb 4, 2026 | $2.03 | $1.99 | $13.34B | $13.70B |
| Oct 28, 2025 | $2.25 | $2.26 | $14.36B | $13.64B |
| Jul 17, 2025 | $2.42 | $2.38 | $14.28B | $13.94B |
| Apr 29, 2025 | $2.28 | $2.12 | $13.62B | $13.90B |
| Jan 31, 2025 | $1.98 | $1.80 | $13.56B | $12.84B |
News
Novartis raised full-year 2026 core operating income guidance after 4% sales growth. Rhapsido peak sales guidance increased to over $4 billion in combined indications.
The Q3 earnings cycle continues to roll along, with several healthcare companies delivering positive results and raising their outlooks as a result.
STOCKHOLM, Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Novartis proprietary antibody. The termination is the result of a Novartis decision to discontinue the program, unrelated…
Novartis, Mitsubishi and Canadian Natural are examples of companies in developed markets outside the U.S. that pass screens for high dividend yields and low volatility for prices and earnings.
Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target
Companies including Santander, Novartis and Standard Chartered say artificial intelligence is beginning to contribute to revenue, costs or profitability. Santander said AI initiatives generated 194 million euros in business value in the first nine months of 2026.
Novartis is rated Hold, with a 12-month price target of $141.81, implying a 12.0% downside from the current share price. My model indicates near-term pressure on selected products, while projected pipeline revenue may support growth over the longer term. NVS trades at a discount to peers on forward P/E but at a premium on EV/EBITDA, producing mixed relative valuation signals.
Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novartis CEO Vas Narasimhan told CNBC on Tuesday that its drug remibrutinib could become "one of our largest medicines in history." But analysts slashed the peak sales forecast for the drug after a late-stage clinical trial for patients with relapsing multiple sclerosis, while reaching its primary endpoint, appeared worse than expected.
Novartis AG ( NVS ) Q3 2026 Earnings Call October 27, 2026 8:00 AM EDT Company Participants Isabella Zinck - Investor Relations Manager Vasant Narasimhan - Chief Executive Officer Mukul Mehta - Chief Financial Officer Conference Call Participants Sachin Jain - BofA Securities, Research Division James Gordon - Barclays Bank PLC, Research Division Florent Cespedes - ODDO BHF Corporate & Markets, Research Division Graham Glyn Parry - Citigroup Inc., Research Division Kerry Holford - Joh. Berenberg,…
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Novartis NYSE: NVS reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core operating income.
LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.
Novartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.
Novartis AG (NYSE:NVS) reported mixed third-quarter earnings on Tuesday as the prized Avidity Biosciences deal worth $12 billion cost the company an estimated $1.9 billion in impairment charges, primarily driven by the timeline shifting due to additional clinical work to be completed.
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Novartis stock rose slightly early Tuesday on strong third-quarter income, but the company's biggest moneymaker, Kisqali, fell short.
The Swiss drugmaker cited solid sales growth and productivity gains, even as recent clinical-trial setbacks hit its bottom line in the third quarter.
Novartis (NYSE: NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton's tyrosine kinase inhibitor reduced relapse rates and MRI lesion activity versus teriflunomide in the REMODEL-1 and REMODEL-2 studies. The company said global regulatory filings are underway, with a U.S. submission expected by the end of the year using